| Open Cancer Trials |
INDICATION |
SUMMARY |
ANEMIA IN NSCLC |
|
Anemia in NSCLC |
Amgen 20070782 – Evaluate the long-term safety and efficacy of darbepoetin alfa administered at 500µg once-every-3-weeks in anemic subjects with advanced stage NSCLC receiving multi-cycle chemotherapy |
BREAST |
|
HER2/ErB2 Positive Primary Breast Cancer
|
CALGB N063D – ALTTO: Adjuvant Lapatinib and/or Trastuzumab treatment optimisation study with HER2/ErB2 positive primary breast cancer |
COLORECTAL |
|
Untreated Metastatic Adenocarcinoma of the Colon or Rectum
|
CALGB S80405 – Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab, or with the combination of Bevacizumab and Cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum |
LUNG |
|
Completely Resected Stage IB-IIIA NSCLC
Non-Small Cell Lung
|
ECOG 1505 – Adjuvant chemotherapy with or without Bevacizumab for patients with completely resected stage IB-IIIA non-small cell lung cancer
CA196-005 –Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as first-line treatment for recurrent or advanced non-small cell lung cancer with non-squamous histology |
MELANOMA |
|
First-Line Therapy for Stage IV Melanoma |
Eisai E7080-702 – E7080 in combination with dacarbazine versus dacarbazine alone |
MULTIPLE MYELOMA |
|
Relapsed Multiple Myeloma |
Novartis CLBH589D2308 – Double-blind, placebo-controlled study of panobinostat in combination with bortezomib and dexamethasone |
NON-HODGKIN’S LYMPHOMA |
|
Rituximab-Refractory, Indolent Non-Hodgkin’s Lymphoma |
Genentech GAO4753g – Bendamustine Compared with Bendamustine + study drug in patients with rituximab-refractory indolent Non-Hodgkin’s lymphoma |
OVARIAN |
|
Platinum-Resistant Ovarian Cancer |
Endocyte EC-FV-06 – Study Drug + Doxorubicin vs. Doxorubicin + Placebo in participants with platinum-resistant ovarian cancer |
PROSTATE |
|
Prostate Cancer Metastatic to Bone |
CALGB 90202 – zoledronic acid (Zometa) to prevent skeletal related events in prostate cancer metastatic to bone |
| |
|
| Helsinn cancer study for nausea and vomiting with chemotherapy. |
| Indication: |
Irritable Bowel Syndrome - Non-Constipation |
| Brief Summary: |
Salix RFIB3007 - Study to assess efficacy and safety of Rifaximin, in subjects with non-constipation irritable bowel syndrome |
| Principal Investigator: |
Nelson L. Ferreira, MD |
| Sub-Investigator: |
James Cremins, MD; Rashid Hanif, MD; Christine Lewis, MD |
| |
|
| Indication: |
Irritable Bowel Syndrome - Diarrhea |
| Brief Summary: |
Measurement of bile acids and fecal fats in irritable bowel syndrome-diarrhea or functional diarrhea in patient's stools |
| Principal Investigator: |
Mary E. Money, MD |
| |
|
| Indication: |
Chronic Constipation |
| Brief Summary: |
Linaclotide 12 weeks administered patients with chronic constipation |
| Principal Investigator: |
Nelson L. Ferreira, MD |
| Sub-Investigators: |
James Cremins, MD; Christine Lewis, MD; Juan A. Tayler, MD |
| |
|
| Indication: |
GERD - Gastroesophageal Reflux Disease |
| Brief Summary: |
Comparing Aaphex 50 mg versus Nexium 40 mg for healing and symptomatic relief |
| Principal Investigator: |
Nelson L. Ferreira, MD |
| Sub-Investigator: |
James Cremins, MD; Christine Lewis, MD; Juan A. Tayler, MD |
| |
|
| Indication: |
Irritable Bowel Syndrome (IBS) - Constipation |
| Brief Summary: |
Linaclotide 12 weeks administered with IBS constipation |
| Principal Investigator: |
Nelson L. Ferreira, MD |
| Sub-Investigator: |
James Cremins, MD; Christine Lewis, MD; Juan A. Tayler, MD |
